Guido Krupp News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Industry News: Merck acquires AmpTec to expand mRNA capabilities for vaccines, treatments and diagnostics Diagnostics business focused on producing customized long RNAs and DNAs for in vitro diagnostics, complements existing Merck portfolio 11 Jan 2021 Merck, a leading science and technology company, has announced the acquisition of AmpTec, a leading Hamburg, Germany-based, mRNA contract development and manufacturing organization (CDMO). The deal strengthens Merck’s capabilities to develop and manufacture mRNA for its customers for use in vaccines, treatments and diagnostics applicable in Covid-19 and many other diseases. Financial terms were not disclosed. “The success of mRNA-based vaccines for Covid-19 lays the path to accelerate the development of these therapeutics for many other diseases,” said Stefan Oschmann, Chairman of the Executive Board and CEO of Merck. “By combining AmpTec’s PCR-based mRNA technology with Merck’s extensive expertise in lipids manufacturi

Stefan oschmannPeter scheinertGuido kruppIndustry newsExecutive boardLife scienceMerck acquires amptec to expand mrna capabilities for vaccinesTreatments and diagnostics the life science business of merck kgaaOperates as milliporesigma in the us and canada merck acquires amptec to expand mrna capabilities for vaccinesTreatments and diagnosticsவழிகாட்டி க்ரப்தொழில் செய்திநிர்வாகி பலகைவாழ்க்கை அறிவியல்சிகிச்சைகள் மற்றும் பரிசோதனை